uPath PD-L1 (SP263) image analysis uses automated pre-computing and one-click scoring to enable quicker and accurate detection and measurement of tumour...

BeyondSpring : 2020 First Quarter Financial Report | MarketScreener

06:49pm, Thursday, 25'th Jun 2020

Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate

12:00am, Thursday, 25'th Jun 2020

Genprex receives USAN Adoption of Generic Drug Name

Merck : FDA Approves Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation | MarketScreener

09:30pm, Wednesday, 24'th Jun 2020

Genprex CEO to Interview Live on “The Big Biz Show”

12:00am, Wednesday, 24'th Jun 2020

Genprex's CEO will interview on the Big Biz Show on Thursday, June 25.

3 Reasons Jazz Pharmaceuticals Is A Hot Buy Right Now | The Motley Fool

11:06am, Tuesday, 23'rd Jun 2020

A new small-cell lung cancer drug approval isn't the only thing the company has going for it.

Bristol Myers Squibb : Supplemental epidemiology information | MarketScreener

03:27pm, Monday, 22'nd Jun 2020

Why Heat Biologics Stock Is Trading Higher Today

02:54pm, Monday, 22'nd Jun 2020

Heat Biologics Inc (NASDAQ: HTBX) shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of PTX-35.Heat Biologics is a

Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35 | | IT Business Net

12:12pm, Monday, 22'nd Jun 2020

DURHAM, NC / ACCESSWIRE / June 22, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate t

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Sign In

Heat Biologics Stock News

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer

Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer

Incyte : Novartis announces MET inhibitor Tabrecta approved in Japan for advanced non-small cell lung cancer with METex14 | MarketScreener

Novartis : announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 | MarketScreener

Genprex Added to Russell 3000® Index

AnHeart Therapeutics Announces Acceptance of Taletrectinib Phase 1 Data for Publication in Clinical Cancer Research

Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm